<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133990</url>
  </required_header>
  <id_info>
    <org_study_id>E7820-701</org_study_id>
    <secondary_id>2009-016015-37</secondary_id>
    <nct_id>NCT01133990</nct_id>
  </id_info>
  <brief_title>FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaBio Development Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Phase Ib portion is to find out the highest dose of study drug that can
      safely be given when tested in a small group of subjects.

      The purpose of the Phase II portion is to find out how safe the study drug is when taken at
      the highest dose in a larger group of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, multicenter, randomized study will consist of a Phase Ib portion: a safety
      run-in period with 3 ascending doses of E7820; and a Phase II portion: a randomized 3-arm
      design. Approximately 135 patients with measurable, nonresectable locally advanced or
      metastatic colorectal adenocarcinoma, who have failed first-line chemotherapy, will be
      enrolled in the study (approximately 15 patients in the Phase Ib portion and 120 patients in
      the Phase II portion). Patients will only participate in either the Phase Ib or the Phase II
      portion of the study. Patients will receive up to a planned total of 6 cycles of study
      treatment unless there is occurrence of progressive disease, unacceptable toxicity,
      withdrawal of consent, withdrawal by the Investigator, lost to follow-up, or death, whichever
      occurs first. After 6 cycles, patients in Arm 3 (FOLFIRI + E7820) who demonstrate clinical
      benefit may continue single agent E7820 for long as clinical benefit is sustained and the
      treatment is well tolerated. If the treating physician does not feel comfortable
      discontinuing chemotherapy after 6 cycles, further chemotherapy may be considered following
      discussion with the medical monitor and sponsor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Parameter: Adverse Events</measure>
    <time_frame>Until study termination; 3 years</time_frame>
    <description>Phase 1B: To determine the MTD of E7820 in combination with FOLFIRI as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7820. Phase II: Safety and tolerability of E7820 at the MTD determined in Phase Ib in combination with FOLFIRI as measured by rate of adverse events by body system and grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Parameter: Concomitant Meds</measure>
    <time_frame>Until study termination; 3 years</time_frame>
    <description>Phase 1B: To determine the MTD of E7820 in combination with FOLFIRI as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7820. Phase II: Safety and tolerability of E7820 at the MTD determined in Phase Ib in combination with FOLFIRI as measured by rate of adverse events by body system and grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Parameter: Lab tests</measure>
    <time_frame>Days 1 and 28 of every cycle until study termination; 3 years</time_frame>
    <description>Phase 1B: To determine the MTD of E7820 in combination with FOLFIRI as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7820. Phase II: Safety and tolerability of E7820 at the MTD determined in Phase Ib in combination with FOLFIRI as measured by rate of adverse events by body system and grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Parameter: ECGs</measure>
    <time_frame>Day 1 and 30 days after termination of therapy; 3 years</time_frame>
    <description>Phase 1B: To determine the MTD of E7820 in combination with FOLFIRI as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7820. Phase II: Safety and tolerability of E7820 at the MTD determined in Phase Ib in combination with FOLFIRI as measured by rate of adverse events by body system and grade.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Parameter</measure>
    <time_frame>Time Frame: Progression-Free Survival (PFS) - Until disease progression or death for 3 years</time_frame>
    <description>Phase 1B: To determine the MTD of E7820 in combination with FOLFIRI as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7820. Phase II: Safety and tolerability of E7820 at the MTD determined in Phase Ib in combination with FOLFIRI as measured by rate of adverse events by body system and grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Parameter</measure>
    <time_frame>Time Frame: Time to progression (TTP) - Until disease progression or death for 3 years</time_frame>
    <description>Phase 1B: To determine the MTD of E7820 in combination with FOLFIRI as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7820. Phase II: Safety and tolerability of E7820 at the MTD determined in Phase Ib in combination with FOLFIRI as measured by rate of adverse events by body system and grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Parameter</measure>
    <time_frame>Time Frame: Objective Response Rate (ORR) - Until disease progression or death for 3 years</time_frame>
    <description>Phase 1B: To determine the MTD of E7820 in combination with FOLFIRI as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7820. Phase II: Safety and tolerability of E7820 at the MTD determined in Phase Ib in combination with FOLFIRI as measured by rate of adverse events by body system and grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Parameter</measure>
    <time_frame>Time Frame: Overall Survival (OS) - Until disease progression or death for 3 years</time_frame>
    <description>Phase 1B: To determine the MTD of E7820 in combination with FOLFIRI as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7820. Phase II: Safety and tolerability of E7820 at the MTD determined in Phase Ib in combination with FOLFIRI as measured by rate of adverse events by body system and grade.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E7820</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI plus Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLIRI</intervention_name>
    <description>The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 and Day 15 of each 28-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional). The 5-FU IV bolus (400 mg/m2) and CIV infusion (2400 mg/m2) over 46 hours is repeated on Days 15 and 16 of each cycle.</description>
    <arm_group_label>FOLIRI</arm_group_label>
    <other_name>leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLIRI plus E7820</intervention_name>
    <description>E7820 is administered orally in tablet form once daily, every day of each 28-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Phase II portion, the dose will be the MTD recommended Phase IB dose in combination with FOLFIRI, as determined during the Phase Ib portion of the study.</description>
    <arm_group_label>E7820</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI plus Bevacizumab</intervention_name>
    <description>Bevacizumab at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle</description>
    <arm_group_label>FOLFIRI plus Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients may be entered in the study only if they meet all of the following criteria:

          1. Male or female patient greater than or equal to 18 years of age;

          2. Histologically or cytologically confirmed nonresectable locally advanced or metastatic
             colorectal adenocarcinoma;

          3. Patients must have failed a first-line chemotherapy regimen for nonresectable locally
             advanced or mCRC (first-line bevacizumab is allowed). Patients randomized to the Phase
             Ib portion can have up to 3 total prior regimens (including adjuvant therapy in
             addition to treatment for advanced disease);

          4. At least 1 site of measurable disease by the Response Evaluation Criteria in Solid
             Tumors (RECIST version 1.1) criteria;

          5. Life expectancy of &gt; 3 months;

          6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1;

          7. Patients must have adequate renal function as evidenced by serum creatinine &lt;2 mg/dL
             and creatinine clearance &gt;50 mL/minute per the Cockcroft and Gault formula;

          8. Patients must have adequate bone marrow function as evidenced by absolute neutrophil
             count (ANC) &gt;1.5 x 109/L, platelets &gt;100 x 109/L, hemoglobin &gt;9.0 g/dL (a hemoglobin
             &lt;9.0 g/dL at Screening is acceptable if it is corrected to &gt;9 g/dL by growth factor or
             transfusion prior to first dose);

          9. Patients must have adequate liver function as evidenced by bilirubin &lt;1.5 times the
             upper limit of the normal range (ULN), and alkaline phosphatase, alanine
             aminotransferase (ALT), and aspartate aminotransferase (AST) &lt;3 X ULN (in the case of
             liver metastases, &lt;5 X ULN). If there are bone metastases, liver-specific alkaline
             phosphatase may be separated from the total and used to assess liver function instead
             of total alkaline phosphatase;

         10. Blood pressure must be well-controlled (&lt;140/90 mmHg at screening) with or without
             antihypertensive medication. Patients must have no history of hypertensive crisis or
             hypertensive encephalopathy;

         11. Male or female patients of child-producing potential must agree to use double barrier
             contraception, oral contraceptives, or avoidance of pregnancy measures during the
             study and for 90 days after the last day of treatment;

         12. Females of childbearing potential must have a negative serum pregnancy test;

         13. Females may not be breastfeeding; and

         14. Ability to understand and willingness to sign a written consent.

        Exclusion Criteria:

        Patients will not be entered in the study for any of the following reasons:

          1. Received chemotherapy, targeted therapy, radiotherapy, surgery, immunotherapy, or
             treatment in another clinical study within the 30 days prior to commencing study
             treatment or have not recovered from side effects of all treatment-related toxicities
             to Grade &lt;1, except for peripheral neuropathy (Grade 1 and Grade 2 are permitted) and
             alopecia;

          2. Previously received irinotecan or irinotecan derivatives;

          3. Previously received anti-alpha 2 integrin therapy;

          4. History of other malignancies except: (1) adequately treated basal or squamous cell
             carcinoma of the skin; (2) curatively treated, a) in situ carcinoma of the uterine
             cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively
             treated solid tumor with no evidence of disease for &gt;5 years;

          5. Presence of brain metastases, unless the patient has received adequate treatment at
             least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids
             for at least 4 weeks prior to randomization;

          6. Are currently receiving any other anticancer treatment;

          7. Palliative radiotherapy is not permitted throughout the study period;

          8. Serious non-healing wound, ulcer, or active bone fracture;

          9. Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to Day 1, or anticipation of need for a major surgical procedure during the
             course of the study;

         10. Refractory nausea and vomiting, malabsorption, significant bowel resection, or any
             other medical condition that would preclude adequate absorption or result in the
             inability to take oral medication;

         11. Significant cardiovascular impairment (history of congestive heart failure New York
             Heart Association [NYHA] Grade &gt;2, unstable angina or myocardial infarction within the
             past 6 months, or serious cardiac arrhythmia);

         12. Active hemoptysis (defined as bright red blood of

         13. Current or recent use (within 7 days) of full-dose warfarin (except low-dose warfarin
             as required to maintain patency of preexisting, permanent indwelling IV catheters).
             For subjects receiving warfarin, International Normalization Ratio (INR) should be
             &lt;1.5. Patients may have prophylactic use of low molecular weight heparin, however
             therapeutic use of heparin or low molecular weight heparin is not acceptable;

         14. History of bleeding diathesis or coagulopathy;

         15. Any history of cerebral vascular accident, transient ischemic attack or â‰¥ Grade 2
             peripheral vascular disease, unless they have had no evidence of active disease for at
             least 6 months prior to randomization;

         16. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6
             months prior to Day 1, unless affected area has been removed surgically;

         17. Patients with organ allografts requiring immunosuppression;

         18. Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen,
             or active hepatitis C positive;

         19. Patients with a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to bevacizumab, irinotecan, 5-FU, or leucovorin;

         20. Hypersensitivity to sulfonamide derivatives; or

         21. Have any medical condition that would interfere with the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harish Dave</last_name>
    <role>Study Director</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Midtown</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates SJ P.A.</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Institute</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Haematology &amp; Oncology Clinic</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>South Australia</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Austin Hospital</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Hospital</name>
      <address>
        <city>Merewether</city>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Nehru Cancer Hospital and Research Centre</name>
      <address>
        <city>Bhopal</city>
        <state>Madhya Pradesh</state>
        <zip>462001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Searoc Cancer Hosptial</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gujarat Cancer &amp; Research Institute</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidwai Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. S. Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Subodh Mitra Cancer Hospital and Research centre</name>
      <address>
        <city>Kolkata</city>
        <zip>700106</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shatabdi Hospital</name>
      <address>
        <city>Nashik</city>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital and Research Center</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noble Hospital</name>
      <address>
        <city>Pune</city>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <zip>632002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCH #2 n.a. N. A. Semashko of LLC &quot;Russian Railways&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Mariinskaya Hospital</name>
      <address>
        <city>St Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute named after N.N. Petr</name>
      <address>
        <city>St Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslav Regional Clinical Oncology Hospital</name>
      <address>
        <city>Yaroslav</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk Regional Anticancer Centre</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #2</name>
      <address>
        <city>Kharkiv</city>
        <zip>61001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The St.Inst. &quot;S.P.Grigoriev Med. Rad.Inst. of AMS of Ukr.&quot;</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod Centr.City Cl.Hosp.,City Onc.Center, UNMU,Fac.of PG</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>India</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <disposition_first_submitted>May 21, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 21, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 29, 2013</disposition_first_posted>
  <last_update_submitted>May 21, 2013</last_update_submitted>
  <last_update_submitted_qc>May 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

